Phase 3 N=37 Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema
Diabetic Macular Edema
Primary: Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor — 1.4905; 0.7140 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=77 Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
HIV-Associated Lipodystrophy Syndrome · Insulin Resistance · HIV Infections
Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1
Phase 4 N=28 Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
Delirium · Postoperative Cognitive Dysfunction
Primary: Incidence of POD — 2; 4 participants
Phase 3 N=945 The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
Status Asthmaticus
Primary: Patients Hospitalization Rate — 82; 75 participants
N/A N=200 Nutritional Support in Pressure Ulcer Patients
Pressure Ulcers
Primary: Rate of Healing — 62.9; 43.4 percent change
Phase 2 N=100 Oral Azithromycin Versus Doxycycline in Posterior Blepharitis
Posterior Blepharitis
Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03
Phase 3 N=1,791 Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Type 2 Diabetes Mellitus
Primary: Primary Major Macrovascular Events — 264; 235 participants — p=<0.05
Phase 3 N=193 Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment — 1.459; 1.465 Liters
Phase 4 N=27 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorders
Primary: Short PTSD Rating Interview (SPRINT) — 16.13; 19.88 units on a scale
Phase 3 N=1,547 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001
Phase 2 N=7 Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
Irritable Bowel Syndrome
Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001
Phase 4 N=79 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women
Overweight
Primary: Body Composition: Dual-energy X-ray Absorptiometry Method — 44.5; 48.8; 43.8; 46.6 percent of total fat mass
Phase 3 N=258 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -11.3; -5.3 scores on a scale — p=<0.001
Phase 4 N=111 Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
Schizophrenia
Primary: Fasting Blood Glucose (FBS) Level (if Fasting Blood Glucose Level Was Not Available, Non-fasting Blood Glucose (Non-FBS) Level) — 0; 0; 1; 4 participants
N/A N=241 A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs
Tooth Disease · Partial Edentulism
Primary: Integration Success of the Implant — 230; 239 implants